NYMXF — Nymox Pharmaceutical Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Nymox Announces U.S. NDA For Fexapotide For BPH
Brief: Nymox Reports 5-Yr Results From Prostate Cancer Study Of Fexapotide Triflutate In 146 U.S. Men
Brief: Nymox Pharmaceutical posts qtrly loss $0.09/shr - SEC filing
Brief: Nymox Pharmaceutical says European member states accepted MAA for fexapotide triflutate
Brief: Nymox Pharmaceutical postpones September 16 AUA meeting
Brief: Nymox announces private placements of $3 million
Brief: Nymox Pharmaceutical Corp posts qtrly loss $0.05/shr - SEC filing
Brief: Nymox files for marketing approval for fexapotide triflutate in Europe
Brief: Nymox expects submission of initial filing seeking approval for Fexapotide Triflutate in next few weeks
Brief: Nymox reports additional positive data from fexapotide BPH phase 3 trial
Brief: Nymox reports successful new phase 3 long-term Fexapotide repeat injection BPH trial results
Brief: Nymox says new phase 3 long-term U.S.results for fexapotide show major decrease in prostate cancer
Brief: Nymox Pharmaceutical announces new long-term fexapotide placebo crossover study results
Brief: Nymox Pharmaceutical announces prostate drug progress
Brief: Nymox Pharmaceutical reports results of prostate cancer study
Brief: Nymox announces prostate cancer clinical trial results from completed 18 month endpoint study
Brief: Nymox announces additional $2.1 mln equity financing
Brief: Nymox Pharma files its Q3 and restated Q2 2015 financial statements
Brief: Nymox says prostate cancer clinical trial will complete prospective 18 month post-treatment assessments